Priority Applications (9) Applications Claiming Priority (1) Related Child Applications (1) Publications (2) Family ID=45879041 Family Applications (2) Family Applications After (1) Country Status (8) Cited By (1) Families Citing this family (6) Citations (1) Family Cites Families (35) 2011 2011-03-25 US US13/072,277 patent/US8609618B2/en active Active 2012 2012-03-08 KR KR1020127027281A patent/KR101445182B1/en not_active Expired - Fee Related 2012-03-08 AU AU2012238087A patent/AU2012238087B2/en active Active 2012-03-08 CN CN2012800013636A patent/CN103327958A/en active Pending 2012-03-08 JP JP2013515592A patent/JP5843853B2/en not_active Expired - Fee Related 2012-03-08 EP EP12710614A patent/EP2547316A2/en not_active Withdrawn 2012-03-08 CA CA2795557A patent/CA2795557C/en active Active 2012-03-08 WO PCT/US2012/028234 patent/WO2012134758A2/en not_active Ceased 2013 2013-10-23 US US14/061,450 patent/US9023801B2/en active Active

Recent epigenetic genome-wide analysis identified low HIF3A methylation levels upregulates HIF3A expression in adipose tissue, thereby leading to adipose tissue dysfunction and adiposity
Get News Across America delivered to your inbox each morning
Contraindications Pregnant or breastfeeding women are usually advised to avoid glutathione injections due to a lack of studies in these populations
EPS: ~$23.50 Forward P/E: ~42 (premium justified by growth) PEG Ratio: ~0.9 (attractive given growth rate) Long-Term Track Record Performance: 52-Week Range: $623.78 - $999.92 1-Year Return: +20-25% (volatile but trending up) Market Leadership: Approaching $1 trillion valuation Dividend Profile: Current Yield: ~0.6% (modest but growing) Annual Dividend: $6.00 per share Growth Rate: Consistently increasing ~15% CAGR The dividend is small now, but management prioritizes reinvestment in R&D while rewarding long-term shareholders with steady increases
IGF-1 LR3 (1mg) For Research Use Only